Tarsus Pharmaceuticals, Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2022 | $-15.3M | $-15.4M | $161.0K | $2.7M |
| Jun 2022 | $-4.3M | $-4.4M | $122.0K | $3.5M |
| Sep 2022 | $-18.6M | $-18.7M | $96.0K | $3.6M |
| Dec 2022 | $-10.9M | $-11.0M | $127.0K | $3.7M |
| Mar 2023 | $-22.0M | $-22.3M | $340.0K | $3.9M |
| Jun 2023 | $-23.8M | $-24.6M | $787.0K | $5.2M |
| Sep 2023 | $-32.4M | $-32.7M | $375.0K | $5.3M |
| Dec 2023 | $-39.3M | $-39.3M | $0 | $5.5M |
| Mar 2024 | $-37.8M | $-38.0M | $174.0K | $5.5M |
| Jun 2024 | $-14.4M | $-15.4M | $1.0M | $7.5M |
| Sep 2024 | $-8.7M | $-8.9M | $282.0K | $7.4M |
| Dec 2024 | $-22.2M | $-22.3M | $72.0K | $7.4M |
| Mar 2025 | $-20.7M | $-21.2M | $590.0K | $6.9M |
| Jun 2025 | $-29.4M | $-30.4M | $1.0M | $8.2M |
| Sep 2025 | $18.3M | $16.3M | $1.9M | $12.2M |
| Dec 2025 | $19.3M | $13.0M | $6.4M | $14.3M |
| Mar 2026 | $-24.7M | $-30.5M | $5.8M | $12.0M |
| Jun 2026 | $61.2M | $57.2M | $4.1M | $13.3M |